SCHEMBL2909581

SCHEMBL2909581

CCC(CO)Nc1nc(NCc2ccc(Cl)c(O)c2O)c2c(n1)c(C(C)C)nn2C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 13/20 0.46
CCNE1 P24864 12/20 0.46
CDK9 P50750 8/20 0.46
CDK5 Q00535 8/20 0.46
CCNT1 O60563 6/20 0.46
CDK5R1 Q15078 5/20 0.46
CDK1 P06493 11/20 0.44
CCNB1 P14635 5/20 0.44
CCNB2 O95067 4/20 0.44
CCNB3 Q8WWL7 4/20 0.44
CACNA1B Q00975 2/20 0.44
CCNE2 O96020 3/20 0.42
CCNT2 O60583 1/20 0.42
AURKA O14965 1/20 0.42
CDK7 P50613 5/20 0.41
CCNH P51946 3/20 0.41
CSNK1D P48730 2/20 0.40
CLK2 P49760 2/20 0.40
CSNK1G2 P78368 2/20 0.40
DYRK1A Q13627 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912208 0.88 CDK2 (0.55) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL2908093 0.86 CDK2 (0.51) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL2911979 0.84 CDK2 (0.39) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL2910404 0.83 BCDIN3D (0.35) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL2913275 0.83 CDK2 (0.47) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL2910257 0.82 CDK2 (0.63) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL2913463 0.82 CDK2 (0.61) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL2908693 0.81 CDK2 (0.47) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL3446730 0.81 CDK2 (0.53) CDK2CCNE1CDK9CDK5CCNT1
SCHEMBL2912848 0.80 CDK2 (0.47) CDK2CCNE1CDK9CDK5CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1348707-B1 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy USTAV EX BOTAN AV CR V V I I O (CZ) 2010-08-25 EP disclosed
US-7745450-B2 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy INSTITUTE OF EXPERIMENTAL BOTANY (CZ) 2010-06-29 US disclosed
US-20050080097-A1 Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF 2005-04-14 US disclosed
EP-1348707-A1 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080097-A1 Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy CBR3, DHFR, AKR1C3 CDK2 685/4885CCNE1 523/4885CDK9 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.